IQ-AI outlines benefits and significance of flagship IB Neuro brand

0 32

IQ-AI Limited (LON:IQAI) has outlined the benefits and the significance of IB Neuro, the flagship brand of its subsidiary Imaging Biometrics (IB), which it said was the first commercially available dynamic susceptibility contrast (DSC) perfusion approach and remains the only platform that automatically generates quantitative output that is spatially validated with biopsy samples by multiple groups and enables objective longitudinal monitoring of treatment.

The company said that in June, Neuro Oncology published their consensus recommendations for the DSC MRI protocol available in IB Neuro, the outcome of a large subcommittee of the Jumpstarting Brain Tumour Drug Development Coalition and provided evidence-based best practices for routine clinical use.

READ: IQ-AI says Imaging Biometrics subsidiary gets IB Clinic software purchase from Keck Medical center

IQ-AI said being the acknowledged standard in dynamic susceptibility contrast imaging was “a notable milestone”, adding that IB remains focused on advancing the field of MR DSC imaging, as recently evidenced by receiving two major grants from the National Institutes of Health (NIH).

“Together, with an outstanding team of clinical and scientific collaborators, IB is well-positioned to further its lead in brain tumour imaging and treatment monitoring and apply those learnings to other cancers and pathologies beyond the brain, setting new standards”, the firm said.

The group also highlighted that in the last 18 months IB has ported its core processing libraries, including the DSC technology in IB Neuro, to standalone software algorithms, which can be networked between any site’s MRI scanners and picture archive and communication systems (PACS) for viewing.

“The true value of IB Neuro’s recommended DSC approach is in its ability to quantify DSC perfusion imaging data regardless of where, when, or on which scanner platform the data are acquired”, IQ-AI said, adding that as more clinicians became aware of the value of the protocol, IB expected “many other hospitals and imaging centres will seek to utilise IB Neuro”.

Shares in IQ-AI jumped 8.1% to 5.7p in late-morning trading on Thursday.

Leave A Reply

Your email address will not be published.